rolipram has been researched along with Obesity in 5 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice." | 7.78 | Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. ( Ahmad, F; Baar, K; Beaven, MA; Brown, AL; Burgin, AB; Chung, JH; Ke, H; Kim, MK; Luo, H; Manganiello, V; Park, SJ; Philp, A; Rehmann, H; Taussig, R; Williams, T, 2012) |
| "Obesity is a major health problem." | 5.40 | The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014) |
| " Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice." | 3.78 | Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. ( Ahmad, F; Baar, K; Beaven, MA; Brown, AL; Burgin, AB; Chung, JH; Ke, H; Kim, MK; Luo, H; Manganiello, V; Park, SJ; Philp, A; Rehmann, H; Taussig, R; Williams, T, 2012) |
| "Obesity is a major health problem." | 1.40 | The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doseyici, S | 1 |
| Mehmetoglu, I | 1 |
| Toker, A | 1 |
| Yerlikaya, FH | 1 |
| Erbay, E | 1 |
| Greene, M | 1 |
| Thackeray, JT | 1 |
| Kenk, M | 2 |
| Thorn, SL | 1 |
| Bevilacqua, L | 1 |
| Harper, ME | 1 |
| Beanlands, RS | 2 |
| Dasilva, JN | 2 |
| Thomas, A | 1 |
| Lortie, M | 1 |
| Dekemp, R | 1 |
| Park, SJ | 1 |
| Ahmad, F | 1 |
| Philp, A | 1 |
| Baar, K | 1 |
| Williams, T | 1 |
| Luo, H | 1 |
| Ke, H | 1 |
| Rehmann, H | 1 |
| Taussig, R | 1 |
| Brown, AL | 1 |
| Kim, MK | 1 |
| Beaven, MA | 1 |
| Burgin, AB | 1 |
| Manganiello, V | 1 |
| Chung, JH | 1 |
| Grønning, LM | 1 |
| Baillie, GS | 1 |
| Cederberg, A | 1 |
| Lynch, MJ | 1 |
| Houslay, MD | 1 |
| Enerbäck, S | 1 |
| Taskén, K | 1 |
1 review available for rolipram and Obesity
| Article | Year |
|---|---|
PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Topics: Animals; Asthma; Brain; Carbon Radioisotopes; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type | 2011 |
4 other studies available for rolipram and Obesity
| Article | Year |
|---|---|
The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity.
Topics: Animals; Colforsin; Cyclic AMP; Cyclic GMP; Diet, High-Fat; Fatty Acids, Nonesterified; Female; Lipo | 2014 |
Reduced in vivo phosphodiesterase-4 response to acute noradrenaline challenge in diet-induced obese rats.
Topics: Animals; Calorimetry, Indirect; Cyclic Nucleotide Phosphodiesterases, Type 4; Desipramine; Dietary F | 2009 |
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue, White; Aging; AMP-Activated Protein Kinase Kina | 2012 |
Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Animals; | 2006 |